Luye Pharma Group Ltd (LUP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Luye Pharma Group Ltd (LUP) has a cash flow conversion efficiency ratio of 0.028x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€344.86 Million ≈ $403.18 Million USD) by net assets (€12.19 Billion ≈ $14.26 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Luye Pharma Group Ltd for the company's overall valuation and market capitalisation.
Luye Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Luye Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Luye Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Luye Pharma Group Ltd ranked by their cash flow conversion efficiency. Explore LUP cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Goldensea Envi Tech C
SHG:603311
|
0.021x |
|
Guangzhou Guangri Stock Co Ltd
SHG:600894
|
0.021x |
|
ASGN Inc
NYSE:ASGN
|
0.047x |
|
Jiangsu Jiangnan Water Co Ltd
SHG:601199
|
0.028x |
|
Dark Horse Beijing Technology Co Ltd
SHE:300688
|
-0.034x |
|
Evergreen International Storage & Transport Corp
TW:2607
|
0.029x |
|
Apotea
ST:APOTEA
|
0.080x |
|
Simply Good Foods Co
NASDAQ:SMPL
|
0.031x |
Annual Cash Flow Conversion Efficiency for Luye Pharma Group Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Luye Pharma Group Ltd from 2016 to 2025. View Luye Pharma Group Ltd stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €18.36 Billion ≈ $21.46 Billion |
€1.78 Billion ≈ $2.08 Billion |
0.097x | +812.06% |
| 2024-12-31 | €15.75 Billion ≈ $18.42 Billion |
€167.76 Million ≈ $196.13 Million |
0.011x | -90.97% |
| 2023-12-31 | €13.53 Billion ≈ $15.82 Billion |
€1.60 Billion ≈ $1.87 Billion |
0.118x | -21.26% |
| 2022-12-31 | €11.04 Billion ≈ $12.91 Billion |
€1.65 Billion ≈ $1.93 Billion |
0.150x | +648.50% |
| 2021-12-31 | €9.11 Billion ≈ $10.66 Billion |
€182.37 Million ≈ $213.21 Million |
0.020x | -84.32% |
| 2020-12-31 | €8.10 Billion ≈ $9.47 Billion |
€1.03 Billion ≈ $1.21 Billion |
0.128x | -15.94% |
| 2019-12-31 | €9.37 Billion ≈ $10.96 Billion |
€1.42 Billion ≈ $1.66 Billion |
0.152x | +15.19% |
| 2018-12-31 | €7.93 Billion ≈ $9.28 Billion |
€1.05 Billion ≈ $1.22 Billion |
0.132x | -5.74% |
| 2017-12-31 | €6.90 Billion ≈ $8.06 Billion |
€964.10 Million ≈ $1.13 Billion |
0.140x | +54.96% |
| 2016-12-31 | €6.56 Billion ≈ $7.67 Billion |
€592.03 Million ≈ $692.14 Million |
0.090x | -- |
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more